This project aims to utilize mass spectrometry (MS) for label-free quantification of the peptide intensity ratio of AIFM1 (Apoptosis-Inducing Factor Mitochondrion-Associated 1) and AK2 (Adenylate Kinase 2) in control (CTRL) and iodoacetamide (IA)-treated FLAG pull-down samples. The approach focuses on analyzing the variations in peptide intensities to understand the differential protein interactions and modifications resulting from IA treatment.